



Programme 2018

12 November, 2018

—

Mount Sinai Goldwurm Auditorium,
New York City, NY, USA

TTS North America – Business Development & Deal Flow for Biotech Mount Sinai, NYC, NY, USA, 12 November 2018

DRAFT: PROGRAM & SPEAKERS SUBJECT TO UPDATE & FINAL CONFIRMATION.

08:30 Registration & Coffee

09:15 Official Opening & Welcoming Introduction to the 9th Annual TTS North America

- Morris S. Berrie, Co-Founder/Chairman, TTS Global Initiative
- Rector, Mount Sinai?
- Eric Lium, Senior Vice President, Mount Sinai Innovation Partners, NYC, NY

09:30 Keynote: Moving innovation to the market.

- Erwin Johnston, Vice President, Corporate Business Development, Eli Lilly and Company, Indianapolis, Indiana

10:15 How is the environment changing in tech transfer / knowledge management? Is the sector more financially independent because of the creation of in-house funds and recognizable investment inflection points? Has this been a driver in improving the sector overall? Has this affected 'indication focus' ie monetizing research?

Moderator: TTS Global Initiative

- Mark Rohrbaugh, Special Advisor to the Director, National Institutes of Health (NIH)
- Erik Lium, Senior Vice President, Mount Sinai Innovation Partners, NYC, NY
- Ofra Weinberger, Director of Licensing, Columbia Technology Ventures (tbc)
- David Kimball, Vice President for Innovation and Research Commercialization, Rutgers University, New Brunswick, NJ

11:00 Coffee & Networking Breakout

11:30 Artificial Intelligence – how close to real impact are we?

- Jack Po, AIMind, Google

12:15 Transactional considerations with relevance to doing deals with international partners.

- Bird & Bird

13:00 Networking Lunch.

TTS North America – Business Development & Deal Flow for Biotech Mount Sinai, NYC, NY, USA, 12 November 2018

DRAFT: PROGRAM & SPEAKERS SUBJECT TO UPDATE & FINAL CONFIRMATION.

14:00 Presentation & Discussion: Has the focus of the NIH evolved?

– Mark Rohrbaugh, Special Advisor to the Director, National Institutes of Health (NIH)

14:45 IP & Patent Law:

– Kevin Noonan, Partner, MBHB LLP, Editor & Co-Founder, Patent Docs, Chicago, Illinois

15:30 Coffee & Networking Breakout.

16:00 Presentation: What do Pharma want now? Are they interested in Central Nervous system diseases? Immuno-Oncology? Antibiotics? Cardiovascular diseases? How can you best look to engage with Pharma when working in these and other high risk areas?

Moderator: Paul Tully, Partner, MBHB LLP, Chicago, Illinois

– John Anthes, Director, Thomas O. Daniel Research Incubator and Collaboration Center, Celgene (tbc)

– John Trainer, Vice-President, Head of Biotech Partnering & Strategy, MedImmune (tbc)

– Jane Rhodes, Executive Director, Business Development & Strategic Alliances, Forma Therapeutics (tbc)

– Sanjeev Munshi, Director Business Development & Licensing, Search & Evaluation Lead, Merck (tbc)

– Brian Kelly, Executive Director, Technology Transfer, Weill Cornell, NYC, NY

16:45 Discussion: Financing of bio sector spinouts, start-ups and SMEs with an eye on the current (capital) markets.

Moderator: TTS Global Initiative

– Charles Baltic, Managing Director, Needham & Co

– Peter Reikes, Vice Chairman, Investments in Healthcare, Stifel, Nicolaus & Co

– Carlo Rizzuto, Partner, Versant Ventures (tbc)

– Cedric Bisson, Partner, Teralys Capital, Montreal, Que., Canada

– Bird&Bird

17:30 Closing summary.

18:00 Close of TTS North America 2018.